4 Stocks Pushing The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average (^DJI) trading up 10 points (0.1%) at 14,085 as of Thursday, Feb. 28, 2013, 12:04 PM ET. The NYSE advances/declines ratio sits at 1,607 issues advancing vs. 1,243 declining with 160 unchanged.

The Health Care sector currently sits up 0.4% versus the S&P 500, which is up 0.2%. Top gainers within the sector include Amgen (AMGN), up 1.9%, Express Scripts (ESRX), up 1.7%, DaVita HealthCare Partners (DVA), up 1.4%, HCA Holdings (HCA), up 1.1% and Sanofi (SNY), up 1.0%. A company within the sector that fell today was Thermo Fisher Scientific (TMO), up 0.4%.

TheStreet Ratings group would like to highlight 4 stocks pushing the sector higher today:

4. Novartis (NVS) is one of the companies pushing the Health Care sector higher today. As of noon trading, Novartis is up $0.79 (1.2%) to $68.11 on average volume Thus far, 1.1 million shares of Novartis exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $67.65-$68.34 after having opened the day at $67.74 as compared to the previous trading day's close of $67.32.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $161.6 billion and is part of the drugs industry. The company has a P/E ratio of 17.2, below the S&P 500 P/E ratio of 17.7. Shares are up 6.4% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Novartis a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Novartis Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1 2 3 4 Next › Last »

 

For more information on Celgene Corporation click any of the following:

• Celgene Corporation Stock Price

• Celgene Corporation Analyst Ratings

• Celgene Corporation Key Stats & Profile

• Celgene Corporation Earnings

• Celgene Corporation Ratio Comparison

• Celgene Corporation Growth Rates

• Celgene Corporation Balance Sheet

• Celgene Corporation Cash Flow

• Celgene Corporation Income Statement